Teachers Retirement System of The State of Kentucky raised its position in Sana Biotechnology, Inc. (NASDAQ:SANA – Get Rating) by 9.5% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 133,061 shares of the company’s stock after acquiring an additional 11,500 shares during the period. Teachers Retirement System of The State of Kentucky owned about 0.07% of Sana Biotechnology worth $2,059,000 as of its most recent SEC filing.
A number of other institutional investors have also recently bought and sold shares of the business. Baillie Gifford & Co. raised its holdings in Sana Biotechnology by 0.6% in the 4th quarter. Baillie Gifford & Co. now owns 11,262,030 shares of the company’s stock valued at $174,337,000 after acquiring an additional 72,198 shares in the last quarter. BlackRock Inc. raised its holdings in Sana Biotechnology by 180.9% in the 3rd quarter. BlackRock Inc. now owns 5,098,670 shares of the company’s stock valued at $114,822,000 after acquiring an additional 3,283,779 shares in the last quarter. Geode Capital Management LLC raised its holdings in Sana Biotechnology by 180.2% in the 3rd quarter. Geode Capital Management LLC now owns 1,541,632 shares of the company’s stock valued at $34,717,000 after acquiring an additional 991,384 shares in the last quarter. Harvard Management Co. Inc. raised its holdings in Sana Biotechnology by 148.2% in the 3rd quarter. Harvard Management Co. Inc. now owns 1,163,601 shares of the company’s stock valued at $26,204,000 after acquiring an additional 694,852 shares in the last quarter. Finally, Morgan Stanley raised its holdings in Sana Biotechnology by 4.6% in the 3rd quarter. Morgan Stanley now owns 898,490 shares of the company’s stock valued at $20,235,000 after acquiring an additional 39,182 shares in the last quarter. 57.02% of the stock is owned by hedge funds and other institutional investors.
Separately, Zacks Investment Research cut Sana Biotechnology from a “hold” rating to a “strong sell” rating in a report on Friday, April 1st.
Shares of SANA opened at $7.55 on Friday. Sana Biotechnology, Inc. has a 1 year low of $5.07 and a 1 year high of $26.60. The stock has a 50 day simple moving average of $7.24 and a 200-day simple moving average of $12.42.
Sana Biotechnology (NASDAQ:SANA – Get Rating) last issued its earnings results on Wednesday, March 16th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.36 by ($1.01). As a group, equities research analysts expect that Sana Biotechnology, Inc. will post -1.41 earnings per share for the current year.
About Sana Biotechnology (Get Rating)
Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others.
- Get a free copy of the StockNews.com research report on Sana Biotechnology (SANA)
- Why is Chevron Stock Falling After Strong Earnings?
- MarketBeat: Week in Review 4/25 – 4/29
- Apple’s Numbers Complete Trifecta
- Rogers Communication Stock Should Be Launching Higher
- O’Reilly Automotive Hits A Pothole
Receive News & Ratings for Sana Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sana Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.